Abstract:Pulmonary arterial hypertension (PAH) is a malignant pulmonary vascular syndrome characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, which eventually leads to right heart failure and even death. Although the exact mechanism of PAH is not fully understood, pulmonary vasoconstriction, vascular remodeling, immune and inflammatory responses, and thrombosis are thought to be involved in the development and progression of PAH. In the era of non-targeted agents, PAH had a very dismal prognosis with a median survival time of only 2.8 years. With the deep understanding of the pathophysiological mechanism of PAH as well as advances in drug research, PAH-specific therapeutic drugs have developed rapidly in the past 30 years, but they primarily focus on the three classical signaling pathways, namely the endothelin pathway, nitric oxide pathway, and prostacyclin pathway. These drugs dramatically improved pulmonary hemodynamics, cardiac function, exercise tolerance, quality of life, and prognosis in PAH patients, but could only reduce pulmonary arterial pressure and right ventricular afterload to a limited extent. Current targeted agents delay the progression of PAH but cannot fundamentally reverse pulmonary vascular remodeling. Through unremitting efforts, new therapeutic drugs such as sotatercept have emerged, injecting new vitality into this field. This review comprehensively summarizes the general treatments for PAH, including inotropes and vasopressors, diuretics, anticoagulants, general vasodilators, and anemia management. Additionally, this review elaborates the pharmacological properties and recent research progress of twelve specific drugs targeting three classical signaling pathways, as well as dual-, sequential triple-, and initial triple-therapy strategies based on the aforementioned targeted agents. More crucially, the search for novel therapeutic targets for PAH has never stopped, with great progress in recent years, and this review outlines the potential PAH therapeutic agents currently in the exploratory stage to provide new directions for the treatment of PAH and improve the long-term prognosis of PAH patients.

Stem/Progenitor Cells and Pulmonary Arterial Hypertension.

Stem/Progenitor Cells And Pulmonary Arterial Hypertension

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Epigenetic Regulation of Pulmonary Arterial Hypertension

Autologous Endothelial Progenitor Cells Transplantation for the Therapy of Primary Pulmonary Hypertension

Regulatory role of autophagy in development of pulmonary artery hypertension

Endothelial Progenitor Cells May Inhibit Apoptosis of Pulmonary Microvascular Endothelial Cells: New Insights into Cell Therapy for Pulmonary Arterial Hypertension

Stem Cells in Pulmonary Hypertension: Current Understanding and Future Challenges.

Potential Role of Cellular Senescence in Pulmonary Arterial Hypertension

Focus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development

Endothelial cells in the pathogenesis of pulmonary arterial hypertension

Endothelial Cell Energy Metabolism, Proliferation, and Apoptosis in Pulmonary Hypertension

Cell Death in Pulmonary Arterial Hypertension

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

Novel insights into the potential applications of stem cells in pulmonary hypertension therapy

Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management

New progress in diagnosis and treatment of pulmonary arterial hypertension

Evidence of Dysfunction of Endothelial Progenitors in Pulmonary Arterial Hypertension.

Panorama of artery endothelial cell dysfunction in pulmonary arterial hypertension

[Advances in molecular mechanism of vascular remodeling in pulmonary arterial hypertension].

Advances in the targeted therapy for pulmonary arterial hypertension